Global leading medical devices provider Mindray submitted its formal application to China Security Regulation Commission to be listed in China’s A share market.
Founded in 1991 and headquartered in Shenzhen, China, Mindray is one of the leading global providers of medical devices and solutions, also the sole Chinese company among top 50 Global Medical Devices.
Despite a Chinese company, Mindray possesses a sound global R&D, marketing and service network with subsidiaries and branch offices in 32 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 31 branch offices in China. Their products and services can be found in healthcare facilities in over 190 countries and regions. In China, Mindray’s products and solutions can be found in nearly 110,000 medical institutions and 99% of Class A tertiary hospitals.
China Life Private Equity Investment Company became its largest external investor during its privatization from the US stock market.
“We are very optimistic in our investment in Mindray. Healthcare industry in China is booming. with rich experience and global leading R&D capabilities, Mindray is on the way to become the excellent representative of Chinese companies in providing high-end medical devices to Chinese users,” said Wan Yiqing, CEO of China Life Private Equity Investment Company.
China Life’s investment in Mindray is viewed as a strategic step by China Life in her practicing “Insurance+medical” business model in extending in allocation in healthcare industry.
“The two sides will further collaborate in various areas including resource consolidation and integration, financial products development to further enhance Mindray’s leading position in the global medical devices, ”added Wan.